From the results of immunohistochemistry, we found that apatinib reduced VEGFR2 and Ki67 and enhanced cleaved caspase-3 and cleaved caspase-9 in synovial sarcoma mice of the treatment group compared to their levels in the mice of the DMSO group (Figure 5(c)). Here, KDR is linked to synovial sarcoma.